HK1058482A1 - Taste masked pharmaceutical compositions - Google Patents

Taste masked pharmaceutical compositions

Info

Publication number
HK1058482A1
HK1058482A1 HK04101310A HK04101310A HK1058482A1 HK 1058482 A1 HK1058482 A1 HK 1058482A1 HK 04101310 A HK04101310 A HK 04101310A HK 04101310 A HK04101310 A HK 04101310A HK 1058482 A1 HK1058482 A1 HK 1058482A1
Authority
HK
Hong Kong
Prior art keywords
taste masked
pharmaceutical compositions
masked pharmaceutical
microcapsule
taste
Prior art date
Application number
HK04101310A
Other languages
English (en)
Inventor
Ulrich Stephen
Zimm Karen
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of HK1058482A1 publication Critical patent/HK1058482A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK04101310A 2001-03-05 2004-02-24 Taste masked pharmaceutical compositions HK1058482A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27347301P 2001-03-05 2001-03-05
PCT/US2002/005795 WO2002069939A2 (en) 2001-03-05 2002-02-26 Taste masked pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK1058482A1 true HK1058482A1 (en) 2004-05-21

Family

ID=23044085

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04101310A HK1058482A1 (en) 2001-03-05 2004-02-24 Taste masked pharmaceutical compositions

Country Status (12)

Country Link
US (1) US6767557B2 (xx)
EP (1) EP1370247B1 (xx)
JP (1) JP2004520420A (xx)
AT (1) ATE391496T1 (xx)
AU (1) AU2002254036A1 (xx)
BR (1) BR0207932A (xx)
CA (1) CA2440069A1 (xx)
DE (1) DE60226012T2 (xx)
HK (1) HK1058482A1 (xx)
MX (1) MXPA03008057A (xx)
MY (1) MY129317A (xx)
WO (1) WO2002069939A2 (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0207930A (pt) * 2001-03-05 2004-03-02 Ortho Mcneil Pharm Inc Composições farmacêuticas lìquidas com sabor mascarado
FR2821747B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Suspension de telithromycine a gout masque
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
AU2003246791A1 (en) * 2002-04-09 2003-10-20 Flamel Technologies Oral suspension of amoxicillin capsules
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
PT1606261E (pt) 2003-03-10 2010-01-11 Nycomed Gmbh Novo processo para a preparação de roflumilast
JP2007501810A (ja) * 2003-08-11 2007-02-01 メルク フロスト カナダ リミテツド 一段階被覆法を用いて作製された着香味遮蔽製薬製剤
US20060013834A1 (en) * 2004-02-24 2006-01-19 Medicis Pediatrics, Inc. Room temperature stable aqueous liquid pharmaceutical composition
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
CA2601250C (en) 2005-03-16 2014-10-28 Nycomed Gmbh Taste masked dosage form containing roflumilast
US20060216355A1 (en) * 2005-03-28 2006-09-28 Donald Spector Encapsulated pharmaceuticals in a medium having non-encapsulated flavoring agents
EP1888025B1 (en) * 2005-06-08 2020-08-12 Basf Corporation Medicament carrier composition and method of forming a film therefrom
US20070264335A1 (en) * 2006-05-09 2007-11-15 Sherman Bernard C Modified release tablets comprising tramadol
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
US8637076B2 (en) * 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
US8007783B2 (en) * 2006-08-22 2011-08-30 Carl Miller Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine
US8304226B2 (en) * 2006-08-22 2012-11-06 Carl Miller Quality of life of hepatitis C patients with a formulation for administration to the oral mucosa including freeze dried lysate of selected Lactobacillus or Bifidobacterium species and N-acetyl D-glucosamine
WO2008098586A1 (en) * 2007-02-13 2008-08-21 Dafra Pharma N.V. Pharmaceutical carrier composition and pharmaceutical composition
WO2008155589A2 (en) * 2007-06-18 2008-12-24 Dolhay Klinika Egészségügyi Kft. Biocide capsules, preparation comprising them and sanitary pad comprising the preparation
US20090065225A1 (en) * 2007-09-07 2009-03-12 Black & Decker Inc. Switchable anti-lock control
MX336355B (es) * 2009-03-04 2016-01-14 Orexo Ab Formulacion resistente al abuso.
EA027618B1 (ru) 2009-05-08 2017-08-31 Эмпликюре Аб Композиция для непрерывной доставки лекарственного средства, содержащая геополимерное связующее
US20110236494A1 (en) * 2010-03-04 2011-09-29 Ranbaxy Laboratories Limited Ciprofloxacin oral suspension
EP2558079B1 (en) 2010-04-12 2019-05-22 S. Zhaveri Pharmakem PVT. Ltd Ciprofloxacin dry syrup composition
CA2809927C (en) 2010-09-07 2019-08-20 Orexo Ab A transdermal drug administration device
JP5976657B2 (ja) * 2011-09-30 2016-08-24 持田製薬株式会社 易服用性固形製剤
WO2013109635A1 (en) 2012-01-16 2013-07-25 Elizabeth Mckenna Compositions and methods for the treatment of hepatic diseases and disorders
WO2014047588A1 (en) 2012-09-21 2014-03-27 Elizabeth Mckenna Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
CA2906172C (en) 2013-03-15 2021-12-21 Aprecia Pharmaceuticals Company Rapidly dispersible dosage form of topiramate
MX364381B (es) 2013-03-15 2019-04-25 Aprecia Pharmaceuticals LLC Forma de dosificacion de oxcarbazepina dispersable rapidamente.
US10098964B2 (en) 2015-03-12 2018-10-16 The Board Of Trustees Of The University Of Illinois Inclusion complexes and methods for making the same
JP6294400B2 (ja) * 2016-07-19 2018-03-14 持田製薬株式会社 易服用性固形製剤
WO2020104837A1 (en) 2018-11-21 2020-05-28 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
US20220401373A1 (en) * 2019-06-17 2022-12-22 Towa Pharmaceutical Co., Ltd. Timed-elution masking particles and oral pharmaceutical composition containing the same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5599556A (en) 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
DE19631084A1 (de) * 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
DK1736144T3 (en) * 1998-05-18 2015-12-07 Takeda Pharmaceutical Orally disintegrating tablets.
CN1161106C (zh) * 1998-07-31 2004-08-11 大塚制药株式会社 具有改良味道的药物组合物
EP1194124B1 (en) * 1999-06-11 2003-09-03 Ranbaxy Laboratories Limited Taste masked compositions
IN192159B (xx) * 2000-05-15 2004-02-28 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
ATE391496T1 (de) 2008-04-15
DE60226012D1 (de) 2008-05-21
AU2002254036A1 (en) 2002-09-19
CA2440069A1 (en) 2002-09-12
MXPA03008057A (es) 2004-10-15
BR0207932A (pt) 2004-03-02
EP1370247A2 (en) 2003-12-17
MY129317A (en) 2007-03-30
US20020197327A1 (en) 2002-12-26
JP2004520420A (ja) 2004-07-08
US6767557B2 (en) 2004-07-27
WO2002069939A2 (en) 2002-09-12
DE60226012T2 (de) 2009-05-14
EP1370247B1 (en) 2008-04-09
WO2002069939A3 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
MY129317A (en) Taste masked pharmaceutical compositions
HUP0301887A3 (en) Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
WO2002011702A3 (en) Hydrogel-driven drug dosage form
AP1748A (en) Chronotherapeutic dosage forms.
YU35302A (sh) Dozirani oblik leka sa inicijalnim hidrogelom
CA2370067A1 (en) Pharmaceutical dosage forms for controlled release producing at least a timed pulse
WO2001062236A3 (en) New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2004056337A3 (en) Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
WO2002053140A3 (en) New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
IL157933A (en) Tetratrate salts of 14,8,5-triazate tetracyclo [9,04.11,02.1.3.10] - Hexadka @ - @@@@@@@@@@@@@ - Penta-An @ and pharmaceuticals containing them
WO2001080826A3 (en) Taste masking coating composition
WO2003028660A3 (en) Drug delivery devices and methods
HK1067524A1 (en) Oral dosage form comprising a therapeutic agent and an adverse-effect agent
SG83819A1 (en) Copolymers having nitrile and alicyclic leaving groups and photoresist compositions comprising same
WO2005027843A3 (en) Chronotherapeutic dosage forms
AU2001291526A1 (en) Sustained release composition containing clarithromycin
WO2004052345A8 (en) Coating composition for taste masking coating and methods for their application and use
WO2005009410A3 (en) Pharmaceutical compositions having a swellable coating
TW200517146A (en) Novel composition
ZA200306545B (en) Medicinal compositions comprising diclofenac and ornoprostil.
WO2002011740A3 (en) 'slow release' pharmaceutical compositions comprising lithium carbonate
AR033431A1 (es) Composiciones farmaceuticas de sabor enmascarado.
WO2002062299A3 (en) Improved controlled release oral dosage form
EP1353624A4 (en) PHARMACEUTICAL COMPOSITIONS OF A NON-GRASS-RESISTANT PROTON PUMP INHIBITOR WITH A CARBONATE AND BICARBONATE SALT COMBINATION
WO2003105811A8 (en) PROGRESSIVE RELEASE COMPOSITIONS AND METHOD OF USE

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120226